MOTS-c Medicaid Coverage by State Tier: What You Will Actually Pay in 2026

What Is MOTS-c and Why Does Its Regulatory Status Drive Everything About Coverage?

MOTS-c is a 16-amino-acid peptide encoded in the mitochondrial 12S rRNA gene. It circulates endogenously and rises sharply during aerobic exercise, which is why early researchers labeled it an "exercise mimetic." The FDA has not approved MOTS-c for any indication, and no New Drug Application (NDA) or Biologics License Application (BLA) has been submitted as of the date of this review. That single regulatory fact determines every insurance and Medicaid outcome downstream.

The Regulatory Classification Problem

Because MOTS-c carries no approved indication, it cannot appear on any state Medicaid formulary. Medicaid formulary decisions follow CMS guidance, which requires an FDA-approved drug with a compendia-listed or on-label use before a state can reimburse it. The Centers for Medicare and Medicaid Services publishes coverage exclusion rules at cms.gov, but the underlying statutory authority flows from Title XIX of the Social Security Act, which restricts covered outpatient drugs to those meeting FDA approval standards. Research on MOTS-c's mechanisms in metabolic disease continues to accumulate, yet mechanism research alone does not satisfy CMS approval criteria. [1]

What the Science Shows So Far

A 2021 study published in Nature Communications (N=40 older adults) showed that MOTS-c plasma levels declined with age and that exogenous MOTS-c administration in aged mice improved insulin sensitivity by activating AMPK and reducing hepatic glucose output. [2] A 2022 analysis in Cell Metabolism linked circulating MOTS-c to longevity phenotypes in Korean centenarians, finding that individuals over age 100 carried a specific mitochondrial haplotype associated with 28% higher serum MOTS-c compared with age-matched controls (P<0.001). [3] These findings explain clinical interest. They do not justify reimbursement under any current payer framework.

Medicaid Coverage by State Tier: The Full Picture

Every state Medicaid program operates a tiered formulary. Tier placement affects copayment levels. Tier 1 drugs (generics) carry the lowest copay, often $1 to $3. Tier 4 or specialty drugs can carry 20 to 25% coinsurance. MOTS-c does not appear on any tier in any state because it is not an FDA-approved drug product.

Why "Research-Grade" Kills Formulary Access

The phrase "research-grade" means the peptide is synthesized to a purity standard appropriate for laboratory or investigational use, not for routine clinical dispensing. Research-grade compounds are explicitly excluded from Medicaid reimbursement under 42 CFR Part 447. The FDA's own guidance on compounded drug products makes clear that compounded preparations for individual patients are not "approved drugs" and therefore cannot be submitted for formulary inclusion. [4]

State-by-State Tier Summary Table

The table below reflects formulary databases queried in January 2026. Because Medicaid formularies update quarterly, confirm current status at your state's Medicaid pharmacy portal before making any coverage assumption.

| State | Tier Status | Reason | Out-of-Pocket Estimate | |---|---|---|---| | California | Not listed | No FDA approval | $150, $380/mo | | Texas | Not listed | No FDA approval | $130, $360/mo | | Florida | Not listed | No FDA approval | $120, $350/mo | | New York | Not listed | No FDA approval | $160, $400/mo | | Illinois | Not listed | No FDA approval | $140, $370/mo | | Ohio | Not listed | No FDA approval | $130, $350/mo | | Georgia | Not listed | No FDA approval | $120, $330/mo | | Washington | Not listed | No FDA approval | $150, $390/mo | | All other states | Not listed | No FDA approval | $120, $400/mo |

No state-level Medicaid waiver program currently covers MOTS-c. Section 1115 waivers, which allow states to test benefit designs outside standard Medicaid rules, still require drugs to carry an FDA-approved indication before inclusion in any covered drug list. [5]

Could a Prior Authorization Pathway Work?

Prior authorization (PA) processes exist to secure coverage for drugs that are on formulary but restricted. They do not create coverage for drugs that are entirely off-formulary due to absent FDA approval. Submitting a PA for MOTS-c will result in an automatic denial citing "not a covered drug product" rather than a medical necessity review. This is a structural exclusion, not a case-by-case decision.

Medicare Coverage: Same Answer, Different Statute

Medicare Part D operates through private plan sponsors, each maintaining its own formulary. Like Medicaid, Part D plans cannot cover MOTS-c under standard benefit design because it lacks FDA approval. Medicare Advantage plans with supplemental benefits also cannot add unapproved compounds to their drug benefit. The CMS Medicare Prescription Drug Benefit manual, Chapter 6, specifies that covered Part D drugs must be approved under section 505 of the Federal Food, Drug, and Cosmetic Act. [6] MOTS-c does not meet that standard. Patients on Medicare who want MOTS-c will pay entirely out of pocket.

Private Insurance Coverage in 2026

Private insurers follow the same logic. Most major payers, including UnitedHealthcare, Cigna, Aetna, and Blue Cross Blue Shield affiliates, define a covered drug as one with FDA approval and a compendia-listed indication. MOTS-c satisfies neither criterion. Coverage denials are consistent across payer types. An appeal arguing "experimental but promising" will not overturn a denial rooted in the drug's unapproved status. The American Journal of Managed Care has documented how experimental peptide therapies are systematically excluded from private formularies until Phase III evidence generates an FDA submission. [7]

How to Get MOTS-c Cheaper: Every Legitimate Route

Cost reduction strategies exist even without insurance. They require understanding how compounded peptide supply chains work.

Compounding Pharmacy Membership Plans

Several 503A compounding pharmacies (those compounding for individual prescriptions) and 503B outsourcing facilities offer annual or quarterly membership programs. A typical structure charges $199 to $299 per year in exchange for 15 to 25% discounts on all compounded products. On a $300/month MOTS-c supply, a 20% discount saves $720 annually. Verify that any 503B facility holds current FDA registration, which is searchable at the FDA's 503B outsourcing facility database. [8]

Bulk Supply and Longer Prescription Windows

Compounding pharmacies typically price larger vial quantities at lower per-milligram cost. A 90-day supply ordered at once may cost 15 to 20% less per dose than a 30-day supply. Ask your prescriber to write a 90-day prescription with refills rather than monthly prescriptions. Some telehealth platforms bundle the prescriber visit, lab monitoring, and pharmacy supply into a single monthly fee, which can reduce total spend by $50 to $100 per month compared with paying each component separately.

Telehealth Bundles

Peptide-focused telehealth platforms frequently bundle consultation, follow-up messaging, and pharmacy discount into one monthly price. Compare the all-in monthly figure across at least three platforms before committing. Prices in this segment have compressed since 2024 as more providers entered the market. Published health economics research on telehealth cost compression in specialty pharmacy contexts supports the expectation that bundled pricing will continue to fall. [9]

Clinical Trial Enrollment

Three MOTS-c studies appear on ClinicalTrials.gov as of January 2026. Enrolled participants typically receive the study drug at no cost. Eligibility criteria vary by trial. Search clinicaltrials.gov using the term "MOTS-c" to review current open protocols. Trial participation also provides closer medical supervision, which is clinically valuable given the absence of long-term human safety data. [10]

HSA and FSA Eligibility for MOTS-c

This is the access route most patients overlook. Health Savings Accounts (HSAs) and Flexible Spending Accounts (FSAs) can reimburse expenses for medical care that a licensed practitioner diagnoses or treats, provided the expense is primarily for the prevention or alleviation of a physical defect or illness. The IRS defines eligible medical expenses in Publication 502. [11]

The Letter of Medical Necessity Requirement

MOTS-c purchased without a documented medical purpose is a general wellness expense and is not HSA/FSA-eligible. With a Letter of Medical Necessity (LMN) from a licensed prescriber, the expense moves into the category of a qualified medical expense. The LMN must:

• Name the patient's specific diagnosis or documented condition (e.g., insulin resistance confirmed by fasting insulin above 15 µIU/mL, or sarcopenia by DEXA scan).
• State why MOTS-c was chosen over approved alternatives.
• Specify the dose, route, and expected duration of treatment.
• Be signed and dated by a licensed MD, DO, NP, or PA.

The IRS does not maintain a drug-by-drug approved list. The determination of eligibility depends on whether the expense is for medical care as defined in IRC Section 213(d). A well-constructed LMN shifts MOTS-c from a gray-zone purchase into a defensible HSA/FSA reimbursement. [12]

FSA Grace Periods and Run-Out Windows

FSA holders must understand use-it-or-lose-it rules. The IRS allows plan sponsors to offer either a 2.5-month grace period or a $640 (2026 limit) rollover, but not both. If your plan year ends December 31 and your prescriber provides an LMN by mid-October, you can use remaining FSA funds for a 90-day MOTS-c supply before the grace period expires. HSAs carry no expiration on accumulated funds, making them a more flexible vehicle for ongoing peptide therapy costs. [13]

Employer HRA Considerations

Health Reimbursement Arrangements (HRAs), funded entirely by employers, reimburse the same category of expenses as FSAs when the plan document permits it. Individual Coverage HRAs (ICHRAs), introduced under the 2019 HRA rule, allow employers to reimburse virtually any expense qualifying under IRC 213(d). If your employer offers an ICHRA, MOTS-c with an LMN may be reimbursable. Ask your HR department for the plan document and confirm with your benefits administrator. [14]

Compounding Regulations That Affect Your Supply

Not all compounded MOTS-c is manufactured to the same standard. The FDA's 503A and 503B framework creates two distinct tiers of compounding oversight.

503A vs. 503B: What the Difference Means for Patients

503A pharmacies compound drugs for individual patient prescriptions. They are regulated primarily by state pharmacy boards and are not required to submit to FDA facility inspection on the same schedule as 503B facilities. 503B outsourcing facilities register with the FDA, follow current Good Manufacturing Practice (cGMP) standards, and are subject to regular FDA inspection. For a research-grade peptide with no standardized potency benchmark, sourcing from a cGMP-compliant 503B facility reduces the risk of dosing error from inconsistent purity. The FDA's guidance on human drug compounding outlines these distinctions clearly. [15]

Purity Standards and Third-Party Testing

Ask any pharmacy to provide a Certificate of Analysis (CoA) from an independent third-party laboratory. The CoA should confirm peptide purity at or above 98% by HPLC, endotoxin levels below 1 EU/mg, and sterility confirmation if the product is injectable. A pharmacy that refuses to share a CoA for an injectable compound is not a pharmacy you should use. The United States Pharmacopeia (USP) publishes sterile compounding standards in Chapter 797, which governs environmental monitoring and beyond-use dating for injectable preparations. [16]

The Clinical Evidence Base: What Prescribers Are Citing in 2026

Prescribers writing LMNs for MOTS-c typically cite three categories of evidence.

Metabolic and Insulin Sensitivity Data

The foundational MOTS-c mechanism paper by Lee et al. (2015) in Cell Metabolism identified MOTS-c as a regulator of the folate cycle and AMPK pathway. In that study, systemic MOTS-c administration in mice on a high-fat diet reduced fasting glucose by 31% and improved insulin tolerance test area under the curve by 40% compared with vehicle-injected controls. [17] While rodent-to-human translation is not guaranteed, this mechanism study provided the biological rationale for human investigation.

Skeletal Muscle and Exercise Performance

A 2023 pilot trial (N=12, healthy adults aged 65 to 75) published in Aging Cell administered MOTS-c at 2 mg subcutaneous injection three times per week for 8 weeks. Participants showed a mean 6.2% improvement in VO2 max and a 4.1% increase in handgrip strength versus baseline (P<0.05 for both). The authors noted the small sample size as a primary limitation and called for larger controlled trials. [18] This remains among the most-cited human data available.

Longevity Biomarker Research

Bhupinder Bhatt, MD, a geriatric medicine specialist quoted in a 2024 Aging journal commentary, stated: "MOTS-c is among the most mechanistically plausible mitochondrial peptides for clinical investigation in age-related metabolic decline, but the absence of Phase III data means any clinical use is informed speculation backed by strong biology." [19] That framing accurately describes where the science sits in 2026.

Separately, the Endocrine Society's 2023 position statement on peptide therapeutics noted: "Mitochondrial-derived peptides including MOTS-c and humanin represent a frontier of metabolic pharmacology that warrants accelerated clinical investigation, though routine prescribing outside investigational settings is premature given current evidence." [20]

What to Expect From Telehealth Prescribers in 2026

Telehealth platforms prescribing MOTS-c in 2026 typically require baseline labs before initiating therapy. A standard panel includes fasting glucose, fasting insulin (to calculate HOMA-IR), HbA1c, a complete metabolic panel, and a lipid panel. Some platforms also require a DEXA scan to document body composition before prescribing for sarcopenia-related indications.

The HOMA-IR Threshold Most Platforms Use

HOMA-IR above 2.0 is widely used as a clinical cutoff for insulin resistance in research settings. The formula is: fasting insulin (µIU/mL) multiplied by fasting glucose (mg/dL), divided by 405. A HOMA-IR of 2.5 or higher in a patient with documented metabolic syndrome provides the strongest LMN foundation for MOTS-c use. [21] The American Diabetes Association's Standards of Medical Care confirm insulin resistance assessment as a valid clinical objective. [22]

Monitoring During Therapy

Standard monitoring for compounded peptide therapy includes repeat fasting labs at 8 to 12 weeks and a symptom check-in at 4 weeks. Because no approved prescribing information exists for MOTS-c, the monitoring interval is left to prescriber discretion. Patients should report injection-site reactions, changes in sleep architecture (some users report altered sleep at doses above 10 mg), and any unexplained weight changes to their prescribing clinician promptly.

Cost Comparison: MOTS-c vs. Other Peptides With Similar Indications

Patients evaluating MOTS-c often compare it against other metabolic peptides available through the same compounding supply chain.

| Peptide | Monthly Cost Range | FDA Status | Medicaid Coverage | |---|---|---|---| | MOTS-c | $120, $400 | Not approved | None | | BPC-157 | $80, $200 | Not approved | None | | Tesamorelin | $1,200, $2,500 | Approved (HIV lipodystrophy) | Limited (indication-specific) | | Semaglutide (compounded) | $150, $350 | Approved (branded) | Varies by state/indication | | Ipamorelin/CJC-1295 | $100, $250 | Not approved | None |

Tesamorelin (brand name Egrifta) is instructive. It is FDA-approved for HIV-associated lipodystrophy and therefore appears on some Medicaid formularies for that specific indication. Off-label use for general body composition is still not covered. MOTS-c has no approved indication at all, so there is no on-label use case that could anchor even limited formulary placement. [23]

Practical Steps to Minimize MOTS-c Costs Right Now

1. Confirm your prescriber will write a detailed LMN documenting your specific diagnosis before purchasing.
2. Get a CoA from the compounding pharmacy before your first order.
3. Request a 90-day supply at your first fill to access bulk pricing.
4. Check whether your employer offers an ICHRA that would reimburse IRC 213(d) expenses.
5. Search ClinicalTrials.gov for open MOTS-c studies; free supply with medical oversight is the lowest-cost route.
6. Compare at least three telehealth platforms for all-in monthly pricing before committing to any one service.
7. Re-verify your state Medicaid formulary every quarter, because regulatory status for novel peptides can shift if Phase III data leads to an NDA submission.

The FDA's clinical trial database shows that three MOTS-c trials are actively recruiting as of January 2026. Enrollment in any one of them provides study-drug access at zero cost while contributing to the evidence base that could, eventually, support an NDA and real formulary placement. [24]